Weidong Han

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 31

Top Venues

Signal transduction and targeted therapy

Department of Molecular Biology, Immunological and Bio-therapeutic, Institute of Basic Medicine, Chinese PLA General Hospital, Beijing, China

Military General Hospital of Beijing PLA (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Department of Molecular Biology, Immunological and Bio-therapeutic, Institute of Basic Medicine, Chinese PLA General Hospital, Beijing, China

China

Professor

Department of Molecular Biology, Immunological and Bio-therapeutic, Institute of Basic Medicine, Chinese PLA General Hospital, Beijing, China

China

Associate professor

Education History

Military General Hospital of Beijing PLA

China

PHD

Shanxi Medical University

China

MSC

Changzhi Medical College

China

BSC

Publications

Qianyi Ming, Jiejie Liu, Zijian Lv, Tiance Wang, Runjia Fan, Yan Zhang, Meixia Chen, Yingli Sun, Weidong Han, Qian Mei
Manganese boosts natural killer cell function via cGAS-STING mediated UTX expression. MedComm 5 (9) (2024)
Liang Dong, Zhi Cao, Meixia Chen, Yang Liu, Xinran Ma, Yuting Lu, Yan Zhang, Kaichao Feng, Yang Zhang, Zhenzhen Meng, Qingming Yang, Yao Wang, Zhiqiang Wu, Weidong Han
Inhibition of glycosphingolipid synthesis with eliglustat in combination with immune checkpoint inhibitors in advanced cancers: preclinical evidence and phase I clinical trial. Nature communications 15 (1) (2024)
Jing Nie, Chunmeng Wang, Liangtao Zheng, Yang Liu, Chengcheng Wang, Yixin Chang, Yudi Hu, Bing Guo, Yuting Pan, Qingming Yang, Xueda Hu, Weidong Han
Epigenetic agents plus anti-PD-1 reshapes tumor microenvironment and restores antitumor efficacy in Hodgkin lymphoma. Blood (2024)
Liang Dong, Zhi Cao, Meixia Chen, Yang Liu, Xinran Ma, Yuting Lu, Yan Zhang, Kaichao Feng, Yang Zhang, Zhenzhen Meng, Qingming Yang, Yao Wang, Zhiqiang Wu, Weidong Han
Inhibition of glycosphingolipid synthesis with eliglustat in combination with immune checkpoint inhibitors in advanced cancers: preclinical evidence and phase I clinical trial. Nature communications 15 (1) (2024)
Liang Dong, Zhi Cao, Meixia Chen, Yang Liu, Xinran Ma, Yuting Lu, Yan Zhang, Kaichao Feng, Yang Zhang, Zhenzhen Meng, Qingming Yang, Yao Wang, Zhiqiang Wu, Weidong Han
Inhibition of glycosphingolipid synthesis with eliglustat in combination with immune checkpoint inhibitors in advanced cancers: preclinical evidence and phase I clinical trial. Nature communications 15 (1) (2024)
Yuzhuo Yang, Yajing Zhang, Xiaoyan Xing, Gang Xu, Xin Lin, Yao Wang, Meixia Chen, Chunmeng Wang, Bin Zhang, Weidong Han, Xiaoyu Hu
IL-6 translation is a therapeutic target of human cytokine release syndrome. The Journal of experimental medicine 220 (11) (2023)
Yao Wang, Chuan Tong, Yuting Lu, Zhiqiang Wu, Yelei Guo, Yang Liu, Jianshu Wei, Chunmeng Wang, Qingming Yang, Weidong Han
Characteristics of premanufacture CD8 + T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma. Signal transduction and targeted therapy 8 (1) (2023)
Jianshu Wei, Xin Lin, Weidong Han
Optimized collaboration of the first and third signals endows robust activity to T cells within the immunocompetent tumor microenvironment. Cellular & molecular immunology (2023)
Chunmeng Wang, Yuting Pan, Yang Liu, Bing Guo, Jinhong Shi, Guanghua Rong, Zhipeng Guo, Zhifang Li, Qingming Yang, Jing Nie, Weidong Han
Long-term complete remission and peripheral biomarkers in Hodgkin lymphoma patients after decitabine-plus-camrelizumab epi-immunotherapy and treatment cessation. MedComm 4 (6) (2023)
Xin Yan, Deyun Chen, Yao Wang, Yelei Guo, Chuan Tong, Jianshu Wei, Yajing Zhang, Zhiqiang Wu, Weidong Han
Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies. Signal transduction and targeted therapy 7 (1) (2022)
Xin Yan, Deyun Chen, Xinran Ma, Yao Wang, Yelei Guo, Jianshu Wei, Chuan Tong, Qi Zhu, Yuting Lu, Yang Yu, Zhiqiang Wu, Weidong Han
CD58 loss in tumor cells confers functional impairment of CAR T cells. Blood advances 6 (22) (2022)
Kaichao Feng, Yang Liu, Yongtian Zhao, Qingming Yang, Liang Dong, Jiejie Liu, Xiang Li, Zhikun Zhao, Qian Mei, Weidong Han
Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study. Journal for immunotherapy of cancer 8 (1) (2021)
Xiaolei Li, Hanren Dai, Xian Li, Ping Li, Weidong Han, Aibin Liang, Weidong Han
Optimal model establishment of whole-process management data for CAR-T therapy in China-how should this be done? Cellular & molecular immunology (2021)
Yao Wang, Chuan Tong, Hanren Dai, Zhiqiang Wu, Xiao Han, Yelei Guo, Deyun Chen, Jianshu Wei, Dongdong Ti, Zongzhi Liu, Qian Mei, Xiang Li, Liang Dong, Jing Nie, Yajing Zhang, Weidong Han
Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming. Nature communications 12 (1) (2021)
Yajing Zhang, Yao Wang, Yang Liu, Chuan Tong, Chunmeng Wang, Yelei Guo, Dongdong Ti, Qingming Yang, Shen Qiao, Zhiqiang Wu, Weidong Han
Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial. Leukemia (2021)
Zhenguang Wang, Na Li, Kaichao Feng, Meixia Chen, Yan Zhang, Yang Liu, Qingming Yang, Jing Nie, Na Tang, Xingying Zhang, Chen Cheng, Lianjun Shen, Jiaping He, Xun Ye, Wei Cao, Haoyi Wang, Weidong Han
Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors. Cellular & molecular immunology 18 (9) (2021)
Chunmeng Wang, Fengxia Shi, Yang Liu, Yajing Zhang, Liang Dong, Xiang Li, Chuan Tong, Yao Wang, Liping Su, Jing Nie, Weidong Han
Correction to: Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy. Journal of hematology & oncology 14 (1) (2021)
Xiaolei Li, Hanren Dai, Hua Wang, Weidong Han
Exploring innate immunity in cancer immunotherapy: opportunities and challenges. Cellular & molecular immunology 18 (6) (2021)
Baolin Liu, Xueda Hu, Kaichao Feng, Ranran Gao, Zhiqiang Xue, Sujie Zhang, Yuanyuan Zhang, Emily Corse, Yi Hu, Weidong Han, Yuanyuan Zhang
Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer. Nature cancer 3 (1) (2021)
Chunmeng Wang, Fengxia Shi, Yang Liu, Yajing Zhang, Liang Dong, Xiang Li, Chuan Tong, Yao Wang, Liping Su, Jing Nie, Weidong Han
Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy. Journal of hematology & oncology 14 (1) (2021)
Yang Liu, Chunmeng Wang, Xiang Li, Liang Dong, Qingming Yang, Meixia Chen, Fengxia Shi, Malcolm Brock, Miao Liu, Qian Mei, Jiejie Liu, Jing Nie, Weidong Han
Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma. Journal for immunotherapy of cancer 9 (4) (2021)
Yelei Guo, Kaichao Feng, Chuan Tong, Hejin Jia, Yang Liu, Yao Wang, Dongdong Ti, Qingming Yang, Zhiqiang Wu, Weidong Han
Efficiency and side effects of anti-CD38 CAR T cells in an adult patient with relapsed B-ALL after failure of bi-specific CD19/CD22 CAR T cell treatment. Cellular & molecular immunology 17 (4) (2020)
Mengze Lyu, Meixia Chen, Rui Zhang, Wen Zhang, Chenguang Wang, Yan Zhang, Xiaoming Wei, Yukun Guan, Jiejie Liu, Kaichao Feng, Miao Jing, Xurui Wang, Yun-Cai Liu, Qian Mei, Weidong Han, Zhengfan Jiang
Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. Cell research 30 (11) (2020)
Jianshu Wei, Yelei Guo, Yao Wang, Zhiqiang Wu, Jian Bo, Bin Zhang, Jun Zhu, Weidong Han
Clinical development of CAR T cell therapy in China: 2020 update. Cellular & molecular immunology 18 (4) (2020)
Xiaolei Li, Zhiqiang Wu, Xiaojing An, Qian Mei, Miaomiao Bai, Leena Hanski, Xiang Li, Tero Ahola, Weidong Han
Correction: Blockade of the LRP16-PKR-NF-κB signaling axis sensitizes colorectal carcinoma cells to DNA-damaging cytotoxic therapy. eLife 9 (2020)
Jianshu Wei, Yang Liu, Chunmeng Wang, Yajing Zhang, Chuan Tong, Guanghai Dai, Wei Wang, John E J Rasko, J Joseph Melenhorst, Weidong Han, Aibin Liang, Weidong Han
The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma. Signal transduction and targeted therapy 5 (1) (2020)
Xiao Han, Yao Wang, Jianshu Wei, Weidong Han
Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy. Journal of hematology & oncology 12 (1) (2019)
Xiaolei Li, Wenhui Song, Changshun Shao, Yufang Shi, Weidong Han
Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy. Cellular & molecular immunology 16 (1) (2018)
Xiaolei Li, Changshun Shao, Yufang Shi, Weidong Han
Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. Journal of hematology & oncology 11 (1) (2018)
Meixia Chen, Jing Nie, Yang Liu, Xiang Li, Yan Zhang, Malcolm V Brock, Kaichao Feng, Zhiqiang Wu, Xiaolei Li, Lu Shi, Suxia Li, Mingzhou Guo, Qian Mei, Weidong Han
Phase Ib/II study of safety and efficacy of low-dose decitabine-primed chemoimmunotherapy in patients with drug-resistant relapsed/refractory alimentary tract cancer. International journal of cancer 143 (6) (2018)
Xiaolei Li, Zhiqiang Wu, Xiaojing An, Qian Mei, Miaomiao Bai, Leena Hanski, Xiang Li, Tero Ahola, Weidong Han
Blockade of the LRP16-PKR-NF-κB signaling axis sensitizes colorectal carcinoma cells to DNA-damaging cytotoxic therapy. eLife 6 (2017)

Weidong Han.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Weidong Han